{
    "name": "estradiol/progesterone",
    "comment": "Rx",
    "other_names": [
        "Bijuva"
    ],
    "classes": [
        "Estrogens/Progestins-HRT"
    ],
    "source": "https://reference.medscape.com/drug/bijuva-estradiol-progesterone-1000294",
    "pregnancy": {
        "common": [
            "Not indicated for women who are premenopausal, pregnant, or lactating",
            "There are no data with use in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to combined hormonal contraceptives (estrogen and progestins) before conception or during early pregnancy"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Estrogens plus progestogens are present in human milk and can reduce milk production in breast-feeding females; this reduction can occur at any time but is less likely to occur once breast-feeding is well-established; the developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Estrogen plus progestin therapy",
                    "description": [
                        "Cardiovascular disorders and probable dementia",
                        "Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia",
                        "Women’s Health Initiative (WHI) Estrogen Plus Progestin substudy reported increased risks of myocardial infarction (MI), stroke, pulmonary embolism (PE), and deep vein thrombosis (DVT) in postmenopausal women (aged 50-79 yr) during 5.6 yr of treatment with daily PO conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) compared with placebo",
                        "WHI Memory Study, a substudy of the WHI study, reported increased risk of developing probable dementia in postmenopausal women aged ≥65 yr during 4 yr of treatment with daily CE 0.625 mg combined with MPA 2.5 mg, compared with placebo",
                        "Breast cancer ",
                        "WHI demonstrated increased risk of invasive breast cancer",
                        "In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA, and other combinations and dosage forms of estrogens and progestins",
                        "Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman"
                    ]
                },
                {
                    "type": "Estrogen-alone therapy",
                    "description": [
                        "Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia",
                        "Women’s Health Initiative (WHI) Estrogen Plus Progestin substudy reported increased risks of myocardial infarction (MI), stroke, pulmonary embolism (PE), and deep vein thrombosis (DVT) in postmenopausal women (aged 50-79 yr) during 5.6 yr of treatment with daily PO conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) compared with placebo",
                        "WHI Memory Study, a substudy of the WHI study, reported increased risk of developing probable dementia in postmenopausal women aged ≥65 yr during 4 yr of treatment with daily CE 0.625 mg combined with MPA 2.5 mg, compared with placebo"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Undiagnosed abnormal genital bleeding",
                "Known, suspected, or history of breast cancer",
                "Known or suspected estrogen-dependent neoplasia",
                "Active DVT, PE, or history of these conditions",
                "Active arterial thromboembolic disease (eg, stroke, MI) or a history of these conditions",
                "Known anaphylactic reaction, angioedema, or hypersensitivity to estradiol, progesterone, or any excipients",
                "Known liver impairment or disease",
                "Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Increased risk of PE, DVT, stroke, and MI with estrogen plus progestin hormone replacement therapy (HRT)",
                "Nonsignificant increased risk for ovarian cancer reported in the WHI estrogen plus progestin substudy",
                "Risk of probable dementia increased in women aged 65-79 yr taking estrogen plus progestin or estrogen alone",
                "A 2- to 4-fold increase for risk of gallbladder disease requiring surgery reported in postmenopausal women receiving estrogens",
                "Estrogen may lead to severe hypercalcemia in women with breast cancer and bone metastases; discontinue therapy if hypercalcemia occurs, and take appropriate measures to reduce serum calcium level",
                "Retinal vascular thrombosis reported in women receiving estrogens; discontinue therapy pending examination if there is a sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine; permanently discontinue therapy if examination reveals papilledema or retinal vascular lesions",
                "Adding progestin for ≥10 days of estrogen administration cycle, or daily with an estrogen continuous regimen, a lowered incidence of endometrial hyperplasia was reported than would be induced by estrogen treatment alone",
                "In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens; in a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen",
                "In women with preexisting hypertriglyceridemia, estrogen therapy may be associated with elevated plasma triglycerides leading to pancreatitis",
                "Estrogens may be poorly metabolized with impaired liver function; caution with history of cholestatic jaundice associated with past estrogen use or with pregnancy",
                "Estrogen administration leads to increased thyroid-binding globulin levels; women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require an increased thyroid replacement dose",
                "Estrogens and progestins cause some degree of fluid retention; caution with conditions that may be affected (eg, cardiac or renal dysfunction); monitor any woman with a condition(s) that might predispose her to fluid retention, such as cardiac or renal impairment; discontinue estrogen plus progestogen therapy, with evidence of medically concerning fluid retention",
                "Estrogen-induced hypocalcemia may occur in women with hypoparathyroidism; consider whether benefits of therapy outweigh risks in such women",
                "Residual endometrial implants reported in women treated post-hysterectomy with estrogen-alone therapy; consider addition of progesterone for these women",
                "Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema; consider whether benefits outweigh risks in such women",
                "Estrogen therapy may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas; consider whether benefits of estrogen therapy outweigh risks in women with such conditions",
                "Serum follicle-stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate-to-severe vasomotor symptoms",
                "Manage appropriately any risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE; for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus)",
                "Increase in risk of stroke demonstrated after first year and persisted; immediately discontinue estrogen with or without progestogen therapy if a stroke occurs or suspected",
                "Venous thromboembolism reported with therapy; increase in VTE risk demonstrated during first year and persisted; immediately discontinue estrogen plus progestogen therapy if a VTE occurs or suspected; if feasible, discontinue estrogens at least 4-6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization",
                "Breast cancer reported with therapy; all women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations; in addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results",
                "Studies of addition of a progestogen for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone; endometrial hyperplasia may be a precursor to endometrial cancer; there are, however, possible risks that may be associated with use of progestogens with estrogens compared to estrogen-alone regimens; these include an increased risk of breast cancer",
                "Estrogens may be poorly metabolized in women with hepatic impairment; exercise caution in any woman with a history of cholestatic jaundice associated with past estrogen use or with pregnancy; in the case of recurrence of cholestatic jaundice, discontinue"
            ],
            "specific": [
                {
                    "type": "Exacerbation of hypothyroidism",
                    "description": [
                        "Estrogen administration leads to increased thyroid-binding globulin (TBG) levels; women with normal thyroid function can compensate for increased TBG by making more thyroid hormone, thus maintaining free T4 and T3 serum concentrations in the normal range",
                        "Women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy; monitor thyroid function in these women during therapy to maintain free thyroid hormone levels in an acceptable range"
                    ]
                },
                {
                    "type": "Endometrial cancer",
                    "description": [
                        "Increased risk of endometrial cancer reported with unopposed estrogen therapy in women with a uterus; endometrial cancer risk among unopposed estrogen users is about 2- to 12-fold greater than in nonusers and appears dependent on treatment duration and estrogen dose",
                        "Clinical surveillance of all women using estrogen-alone or estrogen plus progestogen therapy is important; perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding with unknown etiology",
                        "There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose; adding a progestogen to estrogen therapy in postmenopausal women has been shown to reduce risk of endometrial hyperplasia, which may be a precursor to endometrial cancer"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Estrogens and progestins are metabolized partially by CYP3A4",
                        "CYP3A4 inducers may reduce plasma estrogen/progestin concentration, possibly resulting in decreased therapeutic effect",
                        "CYP3A4 inhibitors may increase plasma concentrations of estrogen/progestin, possibly resulting increased adverse effects"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Breast tenderness",
            "percent": "10.4"
        },
        {
            "name": "Headache",
            "percent": "3.4"
        },
        {
            "name": "Vaginal bleeding",
            "percent": "3.4"
        },
        {
            "name": "Vaginal discharge",
            "percent": "3.4"
        },
        {
            "name": "Pelvic pain",
            "percent": "3.1"
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Abdominal pain and discomfort",
            "percent": null
        },
        {
            "name": "abdominal distention",
            "percent": null
        },
        {
            "name": "diarrhea",
            "percent": null
        },
        {
            "name": "nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "feeling abnormal",
            "percent": null
        },
        {
            "name": "malaise",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Fluid retention",
            "percent": null
        },
        {
            "name": "weight increased",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Muscle spasms",
            "percent": null
        },
        {
            "name": "pain in extremity",
            "percent": null
        },
        {
            "name": "nervous system disorders dizziness",
            "percent": null
        },
        {
            "name": "headache",
            "percent": null
        },
        {
            "name": "somnolence",
            "percent": null
        },
        {
            "name": "psychiatric disorders",
            "percent": null
        },
        {
            "name": "Sleep disorder",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Reproductive system and breast disorders",
            "percent": null
        },
        {
            "name": "Breast pain",
            "percent": null
        },
        {
            "name": "breast tenderness",
            "percent": null
        },
        {
            "name": "uterine bleeding",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders Night sweats",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Hot flush",
            "percent": null
        }
    ]
}